<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="254">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839187</url>
  </required_header>
  <id_info>
    <org_study_id>07 306 02</org_study_id>
    <nct_id>NCT02839187</nct_id>
  </id_info>
  <brief_title>Neuro Imaging and Multimodal Alzheimer's Disease</brief_title>
  <acronym>NIMAD</acronym>
  <official_title>Neuro Imaging and Multimodal Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aimed at measuring cerebral changes in Alzheimer Disease (AD) patients, who&#xD;
      responded to strict physiological criteria typical of AD pathology. The objective of the&#xD;
      present study was to identify the earliest alterations in cerebral connections that could&#xD;
      contribute to the initial episodic memory impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fixing the AV-45 during PET</measure>
    <time_frame>baseline</time_frame>
    <description>compare fixing the AV-45 during a examination emission tomography (PET) between three different groups: healthy subjects, patients with Alzheimer's disease and a mild stage patients of Alzheimer's disease at a pre-dementia stage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deposition of amyloid protein</measure>
    <time_frame>baseline</time_frame>
    <description>Correlation between the deposition of amyloid protein assessed by metabolic imaging (AV-45) and cognitive performance in a group of patients with Alzheimer's disease compared to a control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Cognitive function</measure>
    <time_frame>Baseline</time_frame>
    <description>no memory performance: language (OD 80), executive functions (TMT A and B, evocations formal and categorical lexical, Stroop test, Pyramid-palm tree test Visual and Verbal) praxis visuo-constructive (copy of the figure of Rey) ; working memory (span of front and back numbers, subtest of the WAIS code-III)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific memory evaluation</measure>
    <time_frame>Baseline</time_frame>
    <description>anterograde verbal memory (test Gröber and Buschke), memory unique items (visual DMS48), semantic memory (sub-test information of theWechsler Adult Intelligence Scale (WAIS))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Alzheimer Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will have Neuroimaging by Florbetapir (AV-45)-positron emission tomography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controls will have neuroimaging by AV45-positron emission tomography</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Neuroimaging</intervention_name>
    <description>AV45-positron emission tomography</description>
    <arm_group_label>Controls patients</arm_group_label>
    <arm_group_label>Patients with Alzheimer Disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all subjects :&#xD;
&#xD;
          -  Capacities visual, auditory (authorized devices) and oral or written expression&#xD;
             sufficient for the proper performance of tests&#xD;
&#xD;
          -  Obtain informed written consent of the subject&#xD;
&#xD;
        Patients with AD :&#xD;
&#xD;
          -  Outpatient accompanied by a &quot;helping&quot;&#xD;
&#xD;
          -  No parenchymal lesions allowing isolation explain the symptoms on brain MRI (T1 and&#xD;
             T2) carried more than 6 months prior to enrollment in the study. Patients with more&#xD;
             than three hyperintense white matter or visible lacunar infarction or T2 FLAIR will&#xD;
             not be included in the study.&#xD;
&#xD;
          -  probable Alzheimer's disease diagnosis par with international standards&#xD;
&#xD;
          -  Illness in a mild stage (CDR 1, 24 ≥ Mini-Mental State Examination (MMSE)&gt; 18)&#xD;
&#xD;
          -  activity of daily living (ADL) 4 items&gt; 1/4&#xD;
&#xD;
        Patients with Alzheimer's disease at a pre-dementia stage:&#xD;
&#xD;
          -  Alzheimer's Diagnosis pre-dementia based on the search criteria&#xD;
&#xD;
          -  Illness in a mild stage (CDR 0.5, 30 ≥ MMSE ≥ 25)&#xD;
&#xD;
          -  ADL items ≤ 4 1/4&#xD;
&#xD;
        Control subjects :&#xD;
&#xD;
          -  30 ≥ MMSE ≥ 27&#xD;
&#xD;
          -  perfect autonomy in daily living (IADL = 0, CDR = 0)&#xD;
&#xD;
          -  Neuropsychological evaluation not highlighting of impaired cognitive performance with&#xD;
             focus on memory performance&#xD;
&#xD;
          -  No parenchymal lesions on brain MRI.&#xD;
&#xD;
          -  Lack of family history (first degree) of Alzheimer's disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a contra-indication to MRI (carrying a pacemaker or cardiac&#xD;
             defibrillator, implanted a material activated by an electrical, magnetic or mechanical&#xD;
             carriers hemostatic clips intracerebral aneurysms or carotid artery , holders of&#xD;
             orthopedic implants, claustrophobia)&#xD;
&#xD;
          -  Subjects with clinically significant gastrointestinal, renal, hepatic, endocrine, or&#xD;
             cardiovascular&#xD;
&#xD;
          -  Subjects with a psychiatric disorder or progressive neurological&#xD;
&#xD;
          -  French Language level insufficient to be appropriately involved in neurophysiological&#xD;
             evaluation&#xD;
&#xD;
          -  less than 5 years Education (insufficient understanding level to participate in the&#xD;
             study)&#xD;
&#xD;
          -  Administrative problems: unable to give informed about information, not covered by a&#xD;
             social security system&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients&#xD;
&#xD;
          -  unbalanced diabetes mellitus&#xD;
&#xD;
          -  Subjects treated by a non-steroidal anti-inflammatory&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PARIENTE Jérémie, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Nemmi F, Saint-Aubert L, Adel D, Salabert AS, Pariente J, Barbeau EJ, Payoux P, Péran P. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer's disease patients and healthy subjects. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1408-18. doi: 10.1007/s00259-014-2728-4. Epub 2014 Feb 27.</citation>
    <PMID>24573658</PMID>
  </results_reference>
  <results_reference>
    <citation>Saint-Aubert L, Nemmi F, Péran P, Barbeau EJ, Payoux P, Chollet F, Pariente J. Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging. 2014 May;41(5):836-43. doi: 10.1007/s00259-013-2656-8. Epub 2013 Dec 19.</citation>
    <PMID>24435769</PMID>
  </results_reference>
  <results_reference>
    <citation>Saint-Aubert L, Barbeau EJ, Péran P, Nemmi F, Vervueren C, Mirabel H, Payoux P, Hitzel A, Bonneville F, Gramada R, Tafani M, Vincent C, Puel M, Dechaumont S, Chollet F, Pariente J. Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. EJNMMI Res. 2013 Jun 3;3(1):43. doi: 10.1186/2191-219X-3-43.</citation>
    <PMID>23731789</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 4, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

